Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-21 DOI:10.1080/21645515.2023.2294575

Lixia Yi, Xiaoyan Zhu, Jing Xie, Zhiqiang Meng

引用次数: 0

Abstract

Biliary tract cancer (BTC) is an aggressive malignancy with few options for advanced-stage treatment. The combination of PD-1/PD-L1 inhibitors with famitinib, a receptor tyrosine kinase (RTK) inhib...

查看原文本刊更多论文

SHR-1701 加法米替尼治疗难治性晚期胆囊癌的持久完全反应：病例报告

胆道癌（BTC）是一种侵袭性恶性肿瘤，晚期治疗选择很少。PD-1/PD-L1抑制剂与受体酪氨酸激酶（RTK）抑制剂法米替尼（Famitinib）的联合用药可使胆管癌患者的胆汁...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.